This 50-page special report contains insider information from three leading experts in DM analytics. They review key principles in calculating ROI, how to establish metrics for evaluating DM programs, and common mistakes in measuring ROI. They also share some relevant case studies for […]
Comparative Effectiveness Research blog posting in Healthcare Technology News
Healthcare has never been more enmeshed in the political moment. Ever since the announcement of Don Berwick to lead CMS, opposition centered around Berwick's supposed desire to ration care. Berwick's supporters argue that care is already rationed arbitrarily by insurers. […]
Drug pricing facing threat in new NHS order?
Reform for the National Institute for Health and Clinical Excellence and a switch to value-based pricing are on the agenda as the new coalition government lays out its proposals for the National Health Service. (Source: Pharma Times, May 24, 2010) […]
Comparative Clinical Effectiveness Research (CCER), Health Information Technology (HIT): Future Developments and Impact on Pharma and Providers
Presentation by Jean Paul Gagnon, PhD, Health Policy Consultant […]
Matters Related to Creating New Clinical Trial Designs and Statistics for CER
Presentation by Sheldon Greenfield, MD, Health Policy Research Institute, University of California, Irvine, November 17, 2010 […]
Using Science to Improve the Nation’s Health System: The Case of Comparative Effectiveness Research Presentation
Clinical Trial Simulations With Mathematical Models: Applications to Generate Comparative Effectiveness Research (PPT Presentation)
Presentation by Badri Rengarajan, M.D., Archimedes […]
Why observational studies should be among the tools used in comparative effectiveness research (Presentation)
Examining the Impact of Comparative Effectiveness Research and EVA Data on Health Plan Decision-Making
Presentation by David Gregory, Executive Vice President, Presscott Associates […]
ISPOR Global Health Care Systems Road Map
AHRQ
This fact sheet describes awards made by the Agency for Healthcare Research and Quality (AHRQ) in Fiscal Year (FY) 2010 to support trainees who are focusing on comparative effectiveness research. Funding to support these projects was provided through the American Recovery and Reinvestment of 2009. […]
Health technology assessment and health policy-making in Europe. Current status, challenges and potential
By Marcial Velasco Garrido, Finn Børlum Kristensen, Camilla […]
Comparative Effectiveness Review Methods: Clinical Heterogeneity
This final research report, available in PDF, states that these best practices address critiques from patients, clinicians, policymakers, and others who assert that SRs typically focus on broad populations and, as a result, often lack information relevant to individual patients or patient […]
Comparative Effectiveness: Real-World Evidence of Outcomes
It requires a much broader view of the healthcare system so that information will exist about a patient’s outcome as he or she moves from diagnosis to treatment in the healthcare system. (Source: PharmaVOICE - September 2010) […]
Comparative-Effectiveness Database Debuts
The National Patient Advocate Foundation (NPAF) has created a new Comparative Effectiveness Research (CER) Database available to the public. The new database compiles comparative studies funded by the National Institutes of Health (NIH) and the Agency for Healthcare Research and Quality (AHRQ). The […]
Developing Guidelines To Support Quality Improvement Of Health Economic Publications: PPT Presentation
Health Care Reform: The Uncertain Effectiveness of Comparative Effectiveness Research
Comparative effectiveness research (CER) stands out as the intriguing wild card of health care reform. CER compares competing treatments against each other to determine which interventions work best, supplying critical information for medical decision-making and health policy. If CER works as […]
Interview – Ulf Staginnus on European Cost-Containment Measures and Effects on Healthcare
Ulf Staginnus, is the creator of HealthEconomics Blog and Head Pricing, Health Economics & Outcome Research, Europe, at Novartis Oncology. He talks about the direct implications of recent European cost-containment measures on the pharmaceutical industry. Watch, and learn why the tough times are […]
Is The Impact of Comparative Effectiveness Reports Being Evaluated?
It is clear to all informed persons that the nation needs better evidence of what works in health care, and this has propelled comparative effectiveness research (CER) policy developments of late. (Source: Rebecca Singer Cohen, Bryan Luce, Health Affairs Blog, June 30, 2010) […]
Market access: Risk sharing and alternative pricing schemes
With increasing frequency in Europe, and now starting to show up in the US, biopharma companies and payers are entering into agreements to provide some form of risk sharing or price protection as new drugs are adopted into formularies. (Source: eyeforpharma, August 10, 2010) […]
Modeling Good Research Practices (The Good, The Bad and The Ambiguous) Presentation by Jaime Caro
ISPOR Special Interest Group & Task Force Forum […]
National Institute for Clinical Excellence and its value judgments
Article on the early formation of NICE […]
Study examines UK’s NICE as model producer of HTA
GfK HealthCare, one the largest providers of fully integrated custom health care marketing research in the world, announced today the undertaking of a first-ever research study aimed at examining the UK's National Institute for Health and Clinical Excellence (NICE) as a model producer of Health […]
Exploring Unintended Effects of FDA Diabetes Guidelines – Alogliptin Case Study
Pharma pricing and market access case study […]
Reimbursement and value-based pricing: stratified cost-effectiveness analysis may not be the last word
During recent discussions, it has been argued that stratified cost-effectiveness analysis has a key role in reimbursement decision-making and value-based pricing (VBP). It has previously been shown that when manufacturers are price-takers, reimbursement decisions made in reference to stratified […]
Assessing Comparative Effectiveness Research in the US
by Cohen et al., who support a pluralistic system of CER analyses with a clearinghouse for systematic reviews conducted by multiple evidence-based practice centers, each uniquely suited to its constituency. (Source: Applied Health Economics & Health Policy: December 2009) […]
Value-Based Purchasing and Comparative Effectiveness Research
Value-Based Purchasing and Comparative Effectiveness Research: Why the Pharmaceutical, Biotechnology, and Medical-Surgical Device Industries Should Embrace the Coming Market Evolution. (Source: MarCom Group International, Inc.) […]
AMCP eDossier System
The AMCP eDossier System is a centralized, secure, web-based platform, that provides qualified health care decision makers the opportunity to easily access, review, and evaluate research to make informed, evidence-based decisions. […]
Comparative Effectiveness Research: Relevance and Applications to Pharmacy
Primer in AJHP by Schumock and Pickard, containing a good basic overview. […]
Methods Reference Guide for Effectiveness and Comparative Effectiveness Reviews
Intends to improve the transparency, consistency, and scientific rigor of this work, which consists of systematic reviews of existing research on effectiveness, comparative effectiveness, and comparative harm of different health care interventions. (Source: AHRQ) […]
